Molly Harper Harper Harper

Molly Harper joined Synlogic in Sept. 2021 as Chief Business Officer and is responsible for commercial, corporate development, and business development functions.
Ms. Harper is an experienced biotech leader with a demonstrated track record of translating development assets into commercialized products. Ms. Harper joins Synlogic from Relmada Therapeutics, Inc. where she served as Exec. VP of Operations. Prior to Relmada she served in positions of increasing responsibility with Akcea Therapeutics, including most recently as Senior Vice President and Global Franchise General Manager, with responsibility for a six-drug portfolio, including the commercialization of two rare disease drugs. Ms. Harper was also Head of US Endocrinology in the Rare Disease division of Sanofi Genzyme, having previously served at various positions in sales and marketing with Merck & Co, and equity research at UBS Warburg. She is also a member of the Board of Directors for Catalyst Pharmaceuticals and PreciseDX.